# OnCo record multiple-endocrine-neoplasia (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/multiple-endocrine-neoplasia/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "multiple-endocrine-neoplasia" ;
  schema:name "Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)"@en ;
  schema:alternateName "MEN1"@en, "MEN2A"@en, "MEN2B"@en, "MEN4"@en, "Wermer syndrome"@en, "Sipple syndrome"@en ;
  schema:description "The MEN syndromes are inherited faults in a single gene that cause tumours in several hormone glands over a lifetime. Because the gene can be found in childhood, at-risk relatives can be tested, watched and in MEN2 have the thyroid removed before cancer develops; and for MEN2 thyroid cancer that does spread there is now a precise pill, selpercatinib, that blocks the faulty RET protein."@en ;
  schema:url <https://onco.cc/cancers/multiple-endocrine-neoplasia/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Multiple_endocrine_neoplasia> ;
  schema:citation <https://www.cancer.gov/types/multiple-endocrine-neoplasia>, <https://doi.org/10.1089/thy.2014.0335>, <https://doi.org/10.1210/jc.2012-1230>, <https://doi.org/10.1056/NEJMoa2309719> ;
  onco:tag "nci-coverage", "rare", "endocrine", "hereditary" ;
  onco:related <https://onco.cc/cancers/neuroendocrine/>, <https://onco.cc/cancers/thyroid/>, <https://onco.cc/cancers/pheochromocytoma-paraganglioma/>, <https://onco.cc/cancers/pituitary-tumours/>, <https://onco.cc/cancers/parathyroid-carcinoma/> ;
  onco:technologies <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/prrt/>, <https://onco.cc/technologies/sstr-pet/> ;
  onco:targets <https://onco.cc/targets/ret/>, <https://onco.cc/targets/menin/>, <https://onco.cc/targets/sstr2/> ;
  onco:drugs <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/drugs/pralsetinib/>, <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/drugs/vandetanib/>, <https://onco.cc/drugs/octreotide-lanreotide/>, <https://onco.cc/drugs/everolimus/>, <https://onco.cc/drugs/sunitinib/>, <https://onco.cc/drugs/lutathera/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/> ;
  onco:pathways <https://onco.cc/pathways/rtk-activation/>, <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/oncogene-activation-two-hit/> ;
  onco:terms <https://onco.cc/terms/men1-hereditary-net/>, <https://onco.cc/terms/hereditary-cancer-syndromes/>, <https://onco.cc/terms/germline-vs-somatic/> ;
  onco:trials <https://onco.cc/trials/libretto-531/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-hereditary-risk/>, <https://onco.cc/bottlenecks/b-rare-cancers/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-thakker-j-clin-endocrinol-metab/> ;
  onco:pipeline <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/trials/libretto-531/>, <https://onco.cc/drugs/lutathera/>, <https://onco.cc/drugs/everolimus/> ;
  onco:standardOfCare <https://onco.cc/cancers/thyroid/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/cancers/pheochromocytoma-paraganglioma/>, <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/trials/libretto-531/>, <https://onco.cc/drugs/pralsetinib/>, <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/drugs/vandetanib/>, <https://onco.cc/terms/men1-hereditary-net/>, <https://onco.cc/drugs/octreotide-lanreotide/>, <https://onco.cc/drugs/everolimus/>, <https://onco.cc/drugs/sunitinib/>, <https://onco.cc/drugs/lutathera/>, <https://onco.cc/technologies/prrt/>, <https://onco.cc/cancers/neuroendocrine/> .